/
CGC
$0.99+$0.05 (+5.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$399.3M
422M shares
52-week range
$0.84 – $2.38
10% from low
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
NASDAQ
CS
Borrow rate
32.22%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-240.81
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $226.3M | $398.8M | $546.6M | $475.7M | $333.3M | $297.1M | $269.0M | $284.6M |
| Cost of revenue | $137.4M | $430.5M | $479.7M | $663.1M | $396.8M | $216.3M | $189.5M | $214.9M |
| Gross profit | $88.9M | −$31.7M | $67.0M | −$187.4M | −$63.5M | $80.9M | $79.5M | $69.7M |
| Gross margin | 39.3% | -7.9% | 12.2% | -39.4% | -19.1% | 27.2% | 29.6% | 24.5% |
| R&D | $15.2M | $61.8M | $57.6M | $32.3M | $21.7M | $4.6M | $1.9M | $0 |
| Operating income | −$615.2M | −$1.67B | −$1.24B | −$1.02B | −$2.63B | −$228.7M | −$117.1M | −$73.1M |
| EBITDA | −$567.1M | −$1.38B | −$449.7M | −$53.0M | −$2.88B | −$312.8M | −$479.3M | −$188.2M |
| Net income | −$736.3M | −$1.32B | −$1.74B | −$310.0M | −$3.28B | −$657.3M | −$598.1M | −$262.9M |
| Net margin | -325.3% | -331.3% | -319.2% | -65.2% | -983.7% | -221.2% | -222.4% | -92.4% |
| EPS (diluted) | -1.99 | -3.90 | -4.45 | -7.70 | -70.70 | -8.79 | -5.53 | -0.88 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $245M | $-0.21 | $-0.33–$-0.12 | 2 |
| 2028 | $266M | $-0.18 | $-0.19–$-0.17 | 1 |
| 2029 | $286M | $-0.06 | $-0.06–$-0.05 | 1 |
| 2030 | $305M | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Canopy Growth Corporation Common Shares
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
www.canopygrowth.com- Employees
- 1,128
- IPO / List date
- Apr 7, 2014
- HQ
- SMITH FALLS, A6
Held by traders on TradeandTell
No one on the platform currently holds CGC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CGC as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-12-20 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded CGC yet.
